New combo before surgery aims to control advanced lung cancer

NCT ID NCT07264647

Recruiting now Disease control Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of chemotherapy and immunotherapy (tislelizumab) given before surgery for people with stage III PD-L1 positive non-small cell lung cancer. The goal is to see if this approach helps more patients have successful surgery to remove all cancer. About 30 adults who are current or past smokers and have no specific genetic mutations will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE III NSCLC

Contacts and locations

Locations

Istituti Fisioterapici Ospitalieri
RECRUITING

Rome, Roma (RM), 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.